Skip to content
  • Saturday, 12 September 2026
  • 6:33 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Pharmaceutical R&D

Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition

Teuku Ryan Jun 29, 2026 0

Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…

Read More
Pharmaceutical R&D

Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline

Teuku Ryan Jun 20, 2026 0

Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…

Read More
Pharmaceutical R&D

Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape

Teuku Ryan Apr 25, 2026 0

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…

Read More
Pharmaceutical R&D

Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio

Teuku Ryan Apr 1, 2026 0

Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…

Read More
Science News: A Century of Empowering Public Understanding of ScienceTWiV 1288: Clinical update with Dr. Daniel GriffinRIKEN Physicists Pioneer Robust Nonreciprocal Quantum Synchronization for Phonons Overcoming Environmental Noise and Manufacturing ImperfectionsFDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ